Historically, a range of acetylcholinesterase inhibitors (AChEIs) have been investigated as potential candidates for the symptomatic treatment of AD, including naturally occurring chemicals such as physostigmine, huperzine A, and galantamine, as well as synthetic and semi-synthetic compounds such as tacrine, donepezil, and rivastigmine [10,21]. This evidence concerns the gene ACHE and Alzheimer disease.